Protara Therapeutics, Inc.
TARA
$5.42
$0.163.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.21% | -11.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.26% | -11.01% | |||
| Operating Income | -29.26% | 11.01% | |||
| Income Before Tax | -30.54% | 11.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.54% | 11.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.54% | 11.38% | |||
| EBIT | -29.26% | 11.01% | |||
| EBITDA | -29.40% | 11.01% | |||
| EPS Basic | -19.87% | 11.39% | |||
| Normalized Basic EPS | -19.85% | 11.39% | |||
| EPS Diluted | -19.87% | 11.39% | |||
| Normalized Diluted EPS | -19.85% | 11.39% | |||
| Average Basic Shares Outstanding | 8.92% | 0.00% | |||
| Average Diluted Shares Outstanding | 8.92% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||